{"title":"优化初级保健中慢性肾病和2型糖尿病患者的指导药物治疗。","authors":"Rosalba Santana, Chinweizu Deborah Umana, Zin Thawdar Oo, Shiny Teja Kolli, Vishal Reddy Bejugam, Shobhit Piplani, Amr Aljareh, Bruna Taveras Garcia, Dimitrios Raptis, Chisom Asuzu, Sonam Kumari, Sung Mi Yoon, Archana Vashisht, Meryl Waldman, Vimala Ramasamy, Belinda Jim","doi":"10.1016/j.amjmed.2025.08.029","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite KDIGO (Kidney Disease: Improving Global Outcomes) recommendations for renin-angiotensin-aldosterone system inhibitors (RAASi's) and sodium-glucose cotransporter-2 inhibitors (SGLT2i's) as first-line medications in chronic kidney disease and Type 2 diabetes mellitus patients, implementation gaps persist. We aimed to identify the reasons behind these gaps and develop strategies to address them.</p><p><strong>Methods: </strong>We conducted a retrospective study examining RAASi and SGLT2i prescription patterns among chronic kidney disease and Type 2 diabetes mellitus patients at an inner-city community hospital. Primary care providers were surveyed about barriers to prescribing these medications, after which we implemented an educational intervention and reassessed prescription rates.</p><p><strong>Results: </strong>We identified hyperkalemia and estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m² as major barriers to initiating RAASi's while hyperkalemia and acute kidney injury were the primary limiting factors for medication continuation. Insurance coverage and medication intolerance were the main obstacles to initiating and continuing SGLT2i's respectively. Prior hyperkalemia significantly reduced the odds ratio of RAASi prescription (P = 0.01) whereas urine albumin-creatinine ratio (UACR) screening significantly increased them (P = 0.03). UACR screening within the past year was associated with higher odds of SGLT2i prescription rates (P = 0.019) while insurance status showed no statistically significant impact (P = 0.317). Following educational intervention, annual UACR screening increased by 44%, while prescription rates for SGLT2i's and RAASi's increased by 95% and 4%, respectively. These increased rates were distributed proportionally across racial and ethnic groups.</p><p><strong>Conclusions: </strong>We demonstrated that targeted educational interventions can improve evidence-based care delivery in a racially and ethnically equitable manner. Future research should explore artificial intelligence-based implementation strategies and conduct outcome-based studies.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":5.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimizing guideline-directed medical therapy in chronic kidney disease and type 2 diabetes mellitus patients in primary care.\",\"authors\":\"Rosalba Santana, Chinweizu Deborah Umana, Zin Thawdar Oo, Shiny Teja Kolli, Vishal Reddy Bejugam, Shobhit Piplani, Amr Aljareh, Bruna Taveras Garcia, Dimitrios Raptis, Chisom Asuzu, Sonam Kumari, Sung Mi Yoon, Archana Vashisht, Meryl Waldman, Vimala Ramasamy, Belinda Jim\",\"doi\":\"10.1016/j.amjmed.2025.08.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite KDIGO (Kidney Disease: Improving Global Outcomes) recommendations for renin-angiotensin-aldosterone system inhibitors (RAASi's) and sodium-glucose cotransporter-2 inhibitors (SGLT2i's) as first-line medications in chronic kidney disease and Type 2 diabetes mellitus patients, implementation gaps persist. We aimed to identify the reasons behind these gaps and develop strategies to address them.</p><p><strong>Methods: </strong>We conducted a retrospective study examining RAASi and SGLT2i prescription patterns among chronic kidney disease and Type 2 diabetes mellitus patients at an inner-city community hospital. Primary care providers were surveyed about barriers to prescribing these medications, after which we implemented an educational intervention and reassessed prescription rates.</p><p><strong>Results: </strong>We identified hyperkalemia and estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m² as major barriers to initiating RAASi's while hyperkalemia and acute kidney injury were the primary limiting factors for medication continuation. Insurance coverage and medication intolerance were the main obstacles to initiating and continuing SGLT2i's respectively. Prior hyperkalemia significantly reduced the odds ratio of RAASi prescription (P = 0.01) whereas urine albumin-creatinine ratio (UACR) screening significantly increased them (P = 0.03). UACR screening within the past year was associated with higher odds of SGLT2i prescription rates (P = 0.019) while insurance status showed no statistically significant impact (P = 0.317). Following educational intervention, annual UACR screening increased by 44%, while prescription rates for SGLT2i's and RAASi's increased by 95% and 4%, respectively. These increased rates were distributed proportionally across racial and ethnic groups.</p><p><strong>Conclusions: </strong>We demonstrated that targeted educational interventions can improve evidence-based care delivery in a racially and ethnically equitable manner. Future research should explore artificial intelligence-based implementation strategies and conduct outcome-based studies.</p>\",\"PeriodicalId\":50807,\"journal\":{\"name\":\"American Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjmed.2025.08.029\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjmed.2025.08.029","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Optimizing guideline-directed medical therapy in chronic kidney disease and type 2 diabetes mellitus patients in primary care.
Background: Despite KDIGO (Kidney Disease: Improving Global Outcomes) recommendations for renin-angiotensin-aldosterone system inhibitors (RAASi's) and sodium-glucose cotransporter-2 inhibitors (SGLT2i's) as first-line medications in chronic kidney disease and Type 2 diabetes mellitus patients, implementation gaps persist. We aimed to identify the reasons behind these gaps and develop strategies to address them.
Methods: We conducted a retrospective study examining RAASi and SGLT2i prescription patterns among chronic kidney disease and Type 2 diabetes mellitus patients at an inner-city community hospital. Primary care providers were surveyed about barriers to prescribing these medications, after which we implemented an educational intervention and reassessed prescription rates.
Results: We identified hyperkalemia and estimated glomerular filtration rate (eGFR) below 30 ml/min/1.73m² as major barriers to initiating RAASi's while hyperkalemia and acute kidney injury were the primary limiting factors for medication continuation. Insurance coverage and medication intolerance were the main obstacles to initiating and continuing SGLT2i's respectively. Prior hyperkalemia significantly reduced the odds ratio of RAASi prescription (P = 0.01) whereas urine albumin-creatinine ratio (UACR) screening significantly increased them (P = 0.03). UACR screening within the past year was associated with higher odds of SGLT2i prescription rates (P = 0.019) while insurance status showed no statistically significant impact (P = 0.317). Following educational intervention, annual UACR screening increased by 44%, while prescription rates for SGLT2i's and RAASi's increased by 95% and 4%, respectively. These increased rates were distributed proportionally across racial and ethnic groups.
Conclusions: We demonstrated that targeted educational interventions can improve evidence-based care delivery in a racially and ethnically equitable manner. Future research should explore artificial intelligence-based implementation strategies and conduct outcome-based studies.
期刊介绍：
The American Journal of Medicine - "The Green Journal" - publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. AJM is the official journal of the Alliance for Academic Internal Medicine, a prestigious group comprising internal medicine department chairs at more than 125 medical schools across the U.S. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance and position papers on health care issues, medical education, and public policy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
